POINT MARCHÉS L'Europe clôture dans le rouge, Wall Street hésite à mi-séance

European shares dip ahead of ECB policy decision

Viatris forecasts strong 2024 sales on higher demand for branded drugs

European shares flat on rate-hike jitters; Novo Nordisk jumps

AstraZeneca to Buy CinCor Pharma for Up to $1.8 Billion

Idorsia submits a new drug application to the FDA

Idorsia submits a New Drug Application to the US FDA for aprocitentan for the treatment of patients with difficult-to-control hypertension

Insiders own 33% of Idorsia Ltd (VTX:IDIA) shares but individual investors control 39% of the company

Idorsia initiates OPUS a Phase 3 program to investigate cenerimod for the treatment of patients with systemic lupus erythematosus

Long-term safety and tolerability results with daridorexant in patients with insomnia disorder published in CNS Drugs

Swissmedic approves QUVIVIQ (daridorexant) – a first-in-class treatment for chronic insomnia disorder to improve both nighttime symptoms and daytime functioning

Idorsia and Simcere enter into a licensing agreement for daridorexant in China

QUVIVIQ (daridorexant) – Europe’s first dual orexin receptor antagonist – is now available for patients with chronic insomnia disorder in Italy and Germany

Idorsia congratulates its Chief Scientific Officer Martine Clozel who has been honored by Initiative Switzerland with the Annual Prix Suisse Award

The Lancet and AHA late-breaking science session reports significant and sustained effect of aprocitentan on lowering blood pressure for patients with resistant hypertension

Idorsia (VTX:IDIA) adds CHF156m to market cap in the past 7 days, though investors from three years ago are still down 31%

Invitation to Idorsia's webcast and conference call

Idorsia announces financial results for the first nine months of 2022 – QUVIVIQ becoming a global brand

Invitation to Idorsia's nine-month financial results 2022 webcast and conference call

Idorsia Japan announces positive results with daridorexant in a Phase 3 study of Japanese patients with insomnia